# Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

> **NCT04088110** · PHASE2 · UNKNOWN · sponsor: **Fuzhou General Hospital** · enrollment: 77 (estimated)

## Conditions studied

- Breast Cancer Female
- HER2-positive Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Metastatic Breast Cancer
- Breast Diseases
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Trastuzumab
- **DRUG:** Aromatase Inhibitors

## Key facts

- **NCT ID:** NCT04088110
- **Lead sponsor:** Fuzhou General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11
- **Primary completion:** 2021-11
- **Final completion:** 2023-11
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04088110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04088110, "Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04088110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*